Navigation Links
AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia
Date:6/10/2009

QUEBEC CITY, June 10 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the opening of an extended study in the Phase 3 program with cetrorelix pamoate for the treatment of benign prostatic hyperplasia (BPH), a benign enlargement of the prostate, affecting more than 20 million men in the U.S. alone. Sanofi-aventis U.S. LLC entered into a previously announced agreement with AEterna Zentaris for the development, registration and marketing of cetrorelix in BPH for the U.S. market.

As a result of this collaboration between sanofi-aventis U.S. and AEterna Zentaris, patients completing two years of therapy in the North American trial of cetrorelix, NCT00449150, will be eligible to continue with cetrorelix treatment, according to treatment regimen of the ongoing Phase 3 study, until the end of 2011. Patients entering this extension study will be followed-up for safety, International Prostate Symptom Score (IPSS) and quality of life during the extended treatment, providing follow-up data on cetrorelix for up to 5 years.

Juergen Engel, Ph.D., President and CEO of AEterna Zentaris commented, "We have been pleased with the decision of patients and their physicians to continue into this extended period of open-label treatment follow-up, sponsored by our partner sanofi-aventis U.S. We are confident that patients and their physicians will continue into this extension, as the continuation rate of patients into the open-label part of the study remains at over 90% of those eligible to continue at week 52 and compares favorably with those reported by others.(1) We look forward to presenting the data from the double-blind portion of the study in the next quarter."

About the Phase 3 Program with Cetrorelix in BPH

Cetrorel
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
2. AEterna Zentaris Acquires All Assets from Ardana for Growth Hormone Secretagogue Compound, AEZS-130
3. AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
4. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
5. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
6. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
7. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
8. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
9. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
10. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
11. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report ... Funding” report provides in-depth analysis of the current ... venture capital segments of the financial industry, bearing ... significant impact on the future of emerging biotechnology ... report identifies regions of the world that are ...
(Date:7/29/2014)... The advanced optical methods and applications for ... a revolution in the neurosciences were the inspiration behind ... SPIE, the international society for optics and photonics ... of the BRAIN Initiative in the United States, and ... vision for and provide examples of the impact that ...
(Date:7/29/2014)... LA JOLLA, Calif. , July 29, 2014 /PRNewswire/ ... therapy-based diagnostic and therapeutic company focused on extending the ... have hired Franz Och , Ph.D., an expert ... Chief Data Scientist. Och comes to HLI from Google ... of Google Translate. He will report directly to HLI ...
(Date:7/29/2014)... ultralight foam of atom-thick sheets can be made to ... at Rice University. , In microscopic images, the ... floors and walls that reinforce each other. The structure ... walls of graphene oxide that self-assemble with the assistance ... say the foam could find use in structural components, ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 2SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 3SPIE Launches 'Neurophotonics' Journal with Special Section on BRAIN Initiative 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3Tough foam from tiny sheets 2
... , , , LEXINGTON, Mass. ... holding gmbh announced today the launch of the first human cancer ... targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 ... of cancer by the Wellcome Trust Sanger Institute. , ...
... , , RARITAN, N.J., July 13 ... can accurately predict the prognosis and survival in patients ... published report in the July 10 issue of the ... retrospective study compared how well CTCs and a more ...
... , SAN MARINO, Calif., July 13 ... compounds for HIV/AIDS, autoimmune diseases, and cancer, has retired the majority ... other debt and recently issued new shares. , ... financing through the issuance of shares. This transaction originally was disclosed ...
Cached Biology Technology:First Catalog Cancer Biochip for Sequence Capture Now Available from febit 2Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer 2Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer 3Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer 4Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances 2Viral Genetics Retires Nearly $3.5 Million Convertible Debt and Provides Updates on Capital Structure and Stock Issuances 3
(Date:7/30/2014)... Embryonic stem cells can develop into a multitude of cells ... development into the specific types of mature cells that make ... , One key seems to be long chains of sugars ... Godula,s group at the University of California, San Diego, has ... sugars, but can be more easily manipulated to direct the ...
(Date:7/30/2014)... published online today in the journal Scientific Reports ... Kodra and Auroop Ganguly found that while global temperature ... temperature extremes. For instance, while each year,s average hottest ... also tend to fall within a wider range of ... being observed. This means that even as overall temperatures ...
(Date:7/29/2014)... In the high-tech world of science, researchers sometimes ... Barbara,s Douglas McCauley did just that to study ... muricatum ) on coral reef ecosystems at two ... Using direct observation, animal tracking and computer simulation, ... Ecology, Evolution and Marine Biology, and his colleagues ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2Underwater elephants 2Underwater elephants 3
... at the Oregon National Primate Research Center at Oregon ... gene that appears to control how stem cells become ... implications for the study of Parkinson's disease, brain and ... might be combated by replacing lost or damaged brain ...
... that produce bird feathers have been visualized and analyzed for ... journey that may ultimately shed light on human organ regeneration. ... the journal Nature, was performed by a group of prominent ... University of Southern California. , "What we found is that ...
... team of scientists is proposing that endangered California condors raised ... so that the birds can once again feast on the ... , The researchers from Stanford University and four other institutions ... early condors and their potential prey. Writing in the Nov. ...
Cached Biology News:OHSU discovery sheds light into how stem cells become brain cells 2USC researchers track down the stem cells that create feathers 2USC researchers track down the stem cells that create feathers 3Seal rookeries could provide a reliable food source for endangered California condors, study finds 2Seal rookeries could provide a reliable food source for endangered California condors, study finds 3Seal rookeries could provide a reliable food source for endangered California condors, study finds 4Seal rookeries could provide a reliable food source for endangered California condors, study finds 5
...
... Fully adjustable mixing angle, Variable speed, Digital ... a number of different sized tubes, Spillage ... cultures, keeping biological samples in suspension and ... be used in incubators up to 60C ...
... The DNA Engine Opticon 2 real-time PCR ... LEDs for fluorescence excitation (470-505 nm) and ... nm, 540-700 nm). The Opticon 2 system ... cycler, which includes a thermal gradient feature. ...
... Multicolor capability allows detection of SYBR ... channel, and a range of fluorophores in ... VIC, and TAMRA for a multitude ... discrimination. DNA Engine thermal cycler offers precision ...
Biology Products: